Target Name: HINT2
NCBI ID: G84681
Review Report on HINT2 Target / Biomarker Content of Review Report on HINT2 Target / Biomarker
HINT2
Other Name(s): HINT-2 | HIT-17 | Histidine triad nucleotide binding protein 2 | histidine triad nucleotide-binding protein 2, mitochondrial | Adenosine 5'-monophosphoramidase HINT2 | HIT-17kDa | PKCI-1-related HIT p

HINT2: A Protein with Potential as A Drug Target

HINT2 (HINT-2) is a protein that is expressed in various tissues throughout the body, including the brain, heart, kidneys, and intestines. It is a member of the HINT family of proteins, which are known for their role in cell signaling and inflammation.

One of the key functions of HINT2 is its role in the regulation of inflammation. HINT2 has been shown to play a key role in the production of pro-inflammatory cytokines, such as TNF-alpha, IL-1, and IL-6. These cytokines can cause a range of symptoms, including pain, inflammation, and damage to tissues.

Another function of HINT2 is its role in cell signaling. HINT2 has been shown to play a role in the regulation of several signaling pathways, including the TGF-beta pathway and the NF-kB pathway. These pathways are involved in the regulation of cell growth, differentiation, and inflammation.

Due to its involvement in both inflammation and cell signaling, HINT2 has been identified as a potential drug target. Researchers are currently studying the potential benefits and risks of targeting HINT2, with the goal of developing new treatments for a variety of diseases.

One approach to targeting HINT2 is to use small molecules, such as drugs that inhibit its activity in cell signaling pathways. This approach has been shown to be effective in treating a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Another approach to targeting HINT2 is to use antibodies that specifically recognize and target its surface antigens. This approach has been shown to be effective in treating a variety of diseases, including cancer and autoimmune disorders.

Overall, HINT2 is a protein that has the potential to be a drug target for a variety of diseases. Further research is needed to fully understand its functions and potential benefits.

Protein Name: Histidine Triad Nucleotide Binding Protein 2

Functions: Exhibits adenosine 5'-monophosphoramidase activity, hydrolyzing purine nucleotide phosphoramidates with a single phosphate group such as adenosine 5'monophosphoramidate (AMP-NH2) to yield AMP and NH2 (PubMed:16762638, PubMed:31990367). Hydrolyzes adenosine 5'-O-p-nitrophenylphosphoramidate (AMP-pNA) (PubMed:16762638). Hydrolyzes fluorogenic purine nucleoside tryptamine phosphoramidates in vitro (PubMed:31990367). May be involved in steroid biosynthesis (PubMed:18653718). May play a role in apoptosis (PubMed:16762638)

The "HINT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HINT2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

HINT3 | HIP1 | HIP1R | HIPK1 | HIPK1-AS1 | HIPK2 | HIPK3 | HIPK4 | HIRA | HIRIP3 | HISLA | Histamine Receptor (HR) | Histocompatibility antigen-related | Histone | Histone acetyltransferase (HAT) | Histone deacetylase | Histone H2A | Histone H2B | Histone H3 | Histone Lysine Demethylase | Histone methyltransferase | HIVEP1 | HIVEP2 | HIVEP3 | HJURP | HJV | HK1 | HK2 | HK2P1 | HK3 | HKDC1 | HLA Class II Histocompatibility Antigen DM (HLA-DM) | HLA class II histocompatibility Antigen DO (HLA-DO) | HLA class II histocompatibility antigen DP (HLA-DP) | HLA Class II Histocompatibility Antigen DQ8 | HLA class II histocompatibility antigen DR (HLA-DR) | HLA Class II Histocompatibility Antigen, DQ (HLA-DQ) | HLA class II histocompatibility antigen, DRB1-7 beta chain, transcript variant X1 | HLA complex group 16 (non-protein coding), transcript variant X2 | HLA complex group 8 | HLA-A | HLA-B | HLA-C | HLA-DMA | HLA-DMB | HLA-DOA | HLA-DOB | HLA-DPA1 | HLA-DPA2 | HLA-DPA3 | HLA-DPB1 | HLA-DPB2 | HLA-DQA1 | HLA-DQA2 | HLA-DQB1 | HLA-DQB1-AS1 | HLA-DQB2 | HLA-DRA | HLA-DRB1 | HLA-DRB2 | HLA-DRB3 | HLA-DRB4 | HLA-DRB5 | HLA-DRB6 | HLA-DRB7 | HLA-DRB8 | HLA-DRB9 | HLA-E | HLA-F | HLA-F-AS1 | HLA-G | HLA-H | HLA-J | HLA-K | HLA-L | HLA-N | HLA-P | HLA-U | HLA-V | HLA-W | HLCS | HLF | HLTF | HLX | HM13 | HMBOX1 | HMBS | HMCES | HMCN1 | HMCN2 | HMG20A | HMG20B | HMGA1 | HMGA1P2 | HMGA1P4 | HMGA1P7 | HMGA1P8 | HMGA2 | HMGA2-AS1 | HMGB1